Skip to content
value.today

Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc. is listed today as Palvella Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Pieris Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2019$32 MPrivate placement after listing$10 to $50 million

Pieris Pharmaceuticals, Inc.: Private sale, Nov 2019

Investors in this round

9 investors had bought by the notice of Nov 20, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Pieris Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$32 M of $32 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$796,062
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Ahmed S. Mousa · Executive Officer
  • Hitto R. Kaufmann, Ph.D. · Executive Officer
  • Stephen S. Yoder · Executive Officer, Director
  • Tom R. Bures · Executive Officer
  • Ann S. Barbier, M.D., Ph.D. · Director
  • Christopher S. Kiritsy · Director
  • James S. Geraghty · Director
  • Jean-Pierre S. Bizzari, M.D. · Director
  • Matthew L. Sherman, M.D. · Director
  • Maya R. Said, Sc.D. · Director
  • Michael S. Richman · Director
  • Peter S. Kiener, D.Phil. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • William Blair & Company (CRD 1252) · Chicago, IllinoisSold in CA

Signed by Tom Bures, Vice President, Finance and Treasurer. Source: SEC Form D, newest notice filed Nov 20, 2019. Read the notice at the SEC.

equity, optionsSEC
Jun 2016$17 MPrivate placement after listing$10 to $50 million

Pieris Pharmaceuticals, Inc.: Private sale, Jun 2016

Investors in this round

15 investors had bought by the notice of Jun 15, 2016: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Pieris Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,072,529
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Darlene S. Deptula-Hicks · Executive Officer
  • Stephen S. Yoder · Executive Officer, Director
  • Chau S. Khuong · Director
  • Jean-Pierre S. Bizzari · Director
  • Michael S. Richman · Director
  • Steven S. Prelack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Trout Capital LLC · New York, New YorkSold in CA, IL, MA, NJ, NY
  • Oppenheimer & Co. Inc. · New York, New YorkSold in CA, IL, MA, NJ, NY
  • Cowen and Company, LLC · New York, New YorkSold in CA, IL, MA, NJ, NY

Signed by Darlene Deptula-Hicks, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 15, 2016. Read the notice at the SEC.

equity, optionsSEC
Dec 2014$40 MIssued in a merger or acquisition$10 to $50 million

Pieris Pharmaceuticals, Inc.: Private sale, Dec 2014

Investors in this round

21 investors had bought by the notice of Dec 31, 2014: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Pieris Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Nevada

People named in the notice

  • Darlene M. Deptula-Hicks · Executive Officer · Acting Chief Financial Officer
  • Stephen S. Yoder · Executive Officer, Director · Chief Executive Officer and President
  • Chau M. Khuong · Director · Chairman of the Board of Directors
  • Christina M. Takke · Director
  • Michael M. Richman · Director
  • Steven M. Prelack · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The Issuer entered into a definitive acquisition agreement with Pieris AG and the shareholders of Pieris AG dated as of December 17, 2014.”

Signed by Darlene Deptula-Hicks, Acting Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 31, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pieris Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2019).

    SEC Form D · Nov 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2019

That is all the official record says: Pieris Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Pieris Pharmaceuticals, Inc. are on record.

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Pieris Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Biotechnology Value Fund II LPFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock (Form 3, 2023)SEC Form 3
Biotechnology Value Fund L.P.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023)SEC Form 3
Biotechnology Value Trading Fund OS LPFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock (Form 3, 2023)SEC Form 3
BVF GP Holdings LLCOthernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023)SEC Form 3
BVF I GP LLCOthernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023)SEC Form 3
BVF II GP LLCOthernot statednot statedHeld Series A, B, C, D and E preferred stock (Form 3, 2023)SEC Form 3
BVF Inc/ilFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023)SEC Form 3
BVF Partners L P/ilFund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock, 10% owner (Form 3, 2023)SEC Form 3
BVF Partners OS Ltd.Fund or asset managernot statednot statedHeld Series A, B, C, D and E preferred stock (Form 3, 2023)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Palvella Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pieris Pharmaceuticals, Inc.
NameRoleNamed in
Ahmed S. MousaExecutive officerNov 2019
Hitto R. Kaufmann, Ph.D.Executive officerNov 2019
Stephen S. YoderExecutive officerNov 2019
Tom R. BuresExecutive officerNov 2019
Darlene S. Deptula-HicksExecutive officerJun 2016
Darlene M. Deptula-HicksActing Chief Financial OfficerDec 2014
Ann S. Barbier, M.D., Ph.D.DirectorNov 2019
Christopher S. KiritsyDirectorNov 2019
James S. GeraghtyDirectorNov 2019
Jean-Pierre S. Bizzari, M.D.DirectorNov 2019
Matthew L. Sherman, M.D.DirectorNov 2019
Maya R. Said, Sc.D.DirectorNov 2019
Michael S. RichmanDirectorNov 2019
Peter S. Kiener, D.Phil.DirectorNov 2019
Stephen S. YoderDirectorNov 2019
Chau S. KhuongDirectorJun 2016
Jean-Pierre S. BizzariDirectorJun 2016
Steven S. PrelackDirectorJun 2016
Chau M. KhuongChairman of the Board of DirectorsDec 2014
Christina M. TakkeDirectorDec 2014
Michael M. RichmanDirectorDec 2014
Steven M. PrelackDirectorDec 2014

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.